10-Q/A: Allurion Restates Q2, Faces French Ban & NYSE Delisting Threat

Allurion Technologies, Inc. has restated its Q2 2024 financials due to material weaknesses in internal controls, while facing a sales suspension in France and a NYSE delisting notice.

Summary

• Allurion Technologies, Inc. filed an Amendment No. 1 to its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024, restating previously issued unaudited condensed consolidated financial statements.
• The restatement addresses errors in historical financial statements from Q4 2023 through Q1 2025, primarily affecting Other comprehensive income/loss, Other income/expense, Net income/loss, Accumulated other comprehensive income/loss, and Accumulated deficit.
• The error originated from existing material weaknesses related to insufficient staff with public company and technical accounting experience to maintain proper control activities.
• A 1-to-25 reverse stock split was effected on January 3, 2025, with all financial statements retrospectively adjusted to reflect this.
• For the three months ended June 30, 2024, revenue decreased by 9% to $11.8 million, and gross profit decreased by 10% to $9.0 million, compared to the same period in 2023.
• Net loss for the three months ended June 30, 2024, improved significantly to $(8.3) million from $(22.0) million in the prior year, primarily due to gains from changes in fair value of debt and earn-out liabilities.
• For the six months ended June 30, 2024, revenue decreased by 22% to $21.2 million, and gross profit decreased by 25% to $15.9 million, compared to the same period in 2023.
• Net loss for the six months ended June 30, 2024, improved to $(6.3) million from $(39.8) million in the prior year, driven by similar fair value adjustments.
• Cash and cash equivalents decreased from $38.0 million at December 31, 2023, to $19.3 million at June 30, 2024.
• The company raised $48.0 million in convertible senior secured notes from RTW on April 16, 2024, used to repay the Fortress Term Loan.
• The Revenue Interest Financing Agreement with RTW was amended on April 14, 2024, increasing the royalty rate to RTW from 6% to 12% (for net sales <= $100M prior to Dec 31, 2026) and from 10% to 12% (for net sales <= $100M on or after Jan 1, 2027).
• Subsequent to the quarter, on July 1, 2024, the company closed a public offering and concurrent private placement, raising gross proceeds of $17.3 million and $2.7 million, respectively.
• On August 6, 2024, the French regulatory authority (ANSM) suspended sales of the Allurion Balloon in France, leading to the company's withdrawal from the market pending a remediation plan.
• On August 12, 2024, the company received a NYSE letter for non-compliance with the minimum average closing price requirement ($1.00 per share) over 30 consecutive business days, initiating a six-month cure period.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the financial restatement caused by material weaknesses in internal controls, the significant regulatory setback in France leading to a market withdrawal, and the NYSE delisting threat. While net losses improved, this was largely due to non-cash fair value adjustments, and revenue continues to decline. The need for ongoing capital raises and the 'going concern' warning further underscore the precarious financial position.

Positives

• Net loss significantly improved for both the three months (from $(21.996) million to $(8.322) million) and six months (from $(39.797) million to $(6.326) million) ended June 30, 2024, compared to the prior year, primarily due to non-cash gains from fair value adjustments of debt and earn-out liabilities.
• Operating loss improved by $3.9 million for the three months and $6.4 million for the six months ended June 30, 2024, compared to the prior year, driven by reduced operating expenses.
• Sales and marketing expenses decreased by 35% ($3.6 million) for the three months and 42% ($9.3 million) for the six months ended June 30, 2024, reflecting a focus on more efficient channels and geographies.
• Research and development expenses decreased by 35% ($2.3 million) for the three months and 30% ($4.4 million) for the six months ended June 30, 2024, as the AUDACITY clinical trial nears completion.
• The company successfully refinanced its Fortress Term Loan with $48.0 million in convertible notes from RTW, eliminating a prior debt obligation.
• The AUDACITY clinical trial in the U.S. completed enrollment of 550 patients in Q3 2023, with results expected to support a premarket approval submission to the FDA.

Negatives

• The company is restating previously issued financial statements due to an identified error originating from material weaknesses in internal control over financial reporting, indicating significant accounting deficiencies.
• Revenue decreased by 9% for the three months and 22% for the six months ended June 30, 2024, primarily due to decreased gastric balloon units sold, lower re-order rates, and managing credit risk with distributors.
• Gross profit decreased by 10% for the three months and 25% for the six months ended June 30, 2024, impacted by lower sales volume and increased manufacturing expense due to lower production volumes.
• Cash and cash equivalents decreased by nearly 50% from $38.0 million at December 31, 2023, to $19.3 million at June 30, 2024, indicating significant cash burn.
• The company incurred cash used in financing activities of $(0.7) million for the six months ended June 30, 2024, a significant shift from $17.5 million provided in the prior year.
• The French regulatory authority (ANSM) suspended sales of the Allurion Balloon in France, requiring the company to withdraw the device from the market and implement a remediation plan, which will negatively impact revenue and market presence.
• The company received a NYSE letter for non-compliance with the minimum average closing price requirement ($1.00 per share), putting its stock at risk of delisting.
• The company has an accumulated deficit of $221.3 million as of June 30, 2024, and expects to continue generating significant operating losses for the foreseeable future.
• The Revenue Interest Financing Agreement with RTW was amended to increase the royalty rate from 6% to 12% (and 10% to 12% after Jan 1, 2027), increasing future payment obligations to RTW.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for one year due to recurring losses, expected continued operating losses, and potential non-compliance with financial covenants.
• Material weaknesses in internal control over financial reporting persist, related to insufficient segregation of duties, lack of experienced staff, and inadequate information systems controls, which could lead to further financial reporting errors.
• Failure to achieve and maintain market acceptance of the Allurion Balloon due to competition, perceived efficacy/safety, or patient willingness to pay out-of-pocket could materially and adversely affect financial results.
• Inability to successfully implement a remediation plan to the satisfaction of the French regulatory authority (ANSM) could prevent the resumption of sales in France and negatively impact regulatory approvals in other countries.
• Failure to obtain or maintain regulatory approvals/clearances in the U.S. and other international jurisdictions, or revocation of existing approvals, will prevent product marketing.
• Negative publicity, product defects, or litigation (e.g., product liability claims, adverse events like those in France) could harm the company's reputation and reduce demand.
• The company is not in compliance with NYSE's minimum share price requirement, risking delisting which would reduce liquidity and market price of its common stock.
• The company will need additional funding for future operations and debt service payments and may be unable to raise capital on favorable terms or at all, potentially forcing delays or discontinuation of operations.
• Fluctuations in foreign currency exchange rates could materially impact the business, financial condition, or results of operations, particularly in Europe, the Middle East, and Asia-Pacific regions.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it focuses on obtaining and reinstating regulatory approvals, refining sales and marketing strategies, and enhancing existing products. It anticipates needing additional funding through equity or debt financings and may face delays or discontinuation of product development if unable to raise capital. Research and development expenses are expected to decrease in 2024 as the AUDACITY trial progresses toward completion.

Management Comments

• "We expect to continue to generate significant operating losses for the foreseeable future."
• "Our ability to generate revenue and achieve cost improvements sufficient to achieve profitability will depend on the successful further development and commercialization of our products and receipt and maintenance of regulatory approvals."
• "We intend to monitor the closing bid price of our Common Stock and may, if appropriate, consider available options to regain compliance with the NYSE minimum share price requirement."
• "Although the Company disagrees with ANSM’s decision, it is fully cooperating and in active dialogue with the agency in developing a remediation program prioritizing changes related to its advertising strategy, follow-up program and training programs to address ANSM’s concerns."
• "The Company is committed to continuing its engagement with ANSM to identify a path that will enable the Company to resume the commercialization of the Allurion Balloon in France."

Industry Context

Allurion operates in the highly competitive weight loss industry, offering a unique swallowable intragastric balloon. The launch of the Allurion VCS in the U.S. for various weight loss treatments, including anti-obesity medications and bariatric surgery, indicates an attempt to diversify and leverage AI-powered remote monitoring. However, the regulatory setback in France highlights the stringent and evolving regulatory landscape for medical devices, which can significantly impact market access and commercialization efforts. The company's financial struggles and delisting threat occur amidst a growing global focus on obesity solutions, but also intense competition from pharmaceutical and surgical alternatives.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings, but may become involved in claims related to intellectual property, employee matters, securities class actions, or adverse patient reactions in the normal course of operations.

Related Party Transactions

• RTW: Significant investor and debt holder, involved in $48.0 million convertible notes, public offering, and private placement. Also holds revenue interest financing with increased royalty rates.
• KKG Enterprises, LLC and Remus Group Management, LLC: Consulting agreements for AI platform and advisory services, tied to Krishna Gupta (a director and affiliated with a significant stockholder).
• Hunter Ventures Limited (HVL): Convertible note holder, affiliated with Krishna Gupta.
• Benoit Chardon Consulting (BCC): Corporate officer agreement with former Chief Commercial Officer, terminated December 31, 2023, with a lump-sum termination fee of $0.2 million.

Stakeholder Impact

• Shareholders: Face significant dilution from recent and potential future capital raises, risk of NYSE delisting, and uncertainty regarding the company's ability to achieve profitability and continue as a going concern.
• Employees: Potential impact from cost structure reductions and headcount changes (implied by decreased R&D and S&M salaries), but also benefit from stock-based compensation plans.
• Customers: Impacted by the withdrawal of the Allurion Balloon from the French market, potentially affecting product availability and trust in other regions. Credit risk management also affected sales to certain distributors.
• Creditors (RTW): RTW has a significant financial stake through convertible notes and revenue interest financing, with increased royalty rates and conversion options, indicating a strong position in the company's capital structure.
• Regulatory Authorities: The company is under scrutiny from the SEC (for restatements and internal controls), ANSM (for product safety and advertising in France), and NYSE (for listing compliance).

Next Steps

• Implement and maintain effective internal controls over financial reporting to remediate identified material weaknesses.
• Continue efforts to obtain regulatory approval for products in new markets, including the U.S. FDA AUDACITY clinical trial.
• Successfully complete remediation programs to resume sales of the Allurion Balloon in France and address ANSM's concerns.
• Monitor the common stock's closing bid price and consider options to regain compliance with NYSE minimum share price requirements to avoid delisting.
• Seek Stockholder Approval for the conversion of RTW Convertible Notes beyond 1% of outstanding shares, with a proposal to be included in a definitive proxy statement no later than December 31, 2025.

Key Dates

Recommendation

The filing reveals a confluence of severe negative factors that warrant a strong sell recommendation. The restatement of financials due to material weaknesses in internal controls signals fundamental governance and reporting issues. The immediate suspension of sales in France, a key market, due to safety concerns and the subsequent market withdrawal, represents a significant operational and reputational blow with uncertain resolution. Furthermore, the NYSE delisting notice due to a sub-$1.00 share price indicates extreme market distress and poses a severe threat to liquidity and investor confidence. While net losses have technically improved, this is largely due to non-cash accounting adjustments, and underlying revenue continues to decline. The 'going concern' warning, coupled with ongoing capital raises that dilute existing shareholders, paints a picture of a company in a highly precarious financial and operational state. A seasoned investor would recognize these as critical red flags, suggesting a high probability of further value erosion.

Keywords

Allurion Technologies, ALUR, SEC Filing, 10-Q/A, Financial Restatement, Internal Controls, Weight Loss Device, Allurion Balloon, Medical Device, Regulatory Suspension, France Market, NYSE Delisting, Convertible Notes, Capital Raise, Financial Performance, Operating Losses, Going Concern, AUDACITY Clinical Trial, RTW Investment